I

IGM Biosciences
D

IGMS

1.38000
USD
-0.02
(-1.08%)
مغلق
حجم التداول
3,149
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
82,060,570
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: IGM Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.